Bayer files oral contraceptive Qlaira in US
This article was originally published in Scrip
Executive Summary
Bayer has submitted a US NDA for its new estradiol-based oral contraceptive Qlaira (estradiol valerate/dienogest) for indications of oral contraception and the treatment of heavy and/or prolonged menstrual bleeding.